Search research articles
Contact Us
Filters
Showing results (11-20 of 62) with videos related to
Page
of 7
Sort By:
Frontiers in Oncology
|
August 9, 2014
The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics
Edward Hammond, Ashwani Khurana, Viji Shridhar, et al.
FEBS Open Bio
|
November 20, 2013
Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues
Edward Hammond, Paul Handley, Keith Dredge, et al.
Journal of AHIMA
|
August 12, 2009
Healthcare standards development. The value of nurturing collaboration
William Edward Hammond, Charles Jaffe, Rebecca Daniels Kush
Bioorganic & Medicinal Chemistry
|
October 31, 2007
Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88
Jon K Fairweather, Edward Hammond, Ken D Johnstone, et al.
Organic & Biomolecular Chemistry
|
August 19, 2007
Enantiospecific synthesis of the heparanase inhibitor (+)-trachyspic acid and stereoisomers from a common precursor
Steven C Zammit, Vito Ferro, Edward Hammond, et al.
British Journal of Clinical Pharmacology
|
July 10, 2023
The new big is small: Leveraging knowledge from small trials for rare disease drug development: Blarcamesine for Rett syndrome
Ene I Ette, Emmanuel O Fadiran, Christopher Missling, et al.
BMJ Open
|
November 19, 2015
Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study
Derek J Ward, Edward Hammond, Luan Linden-Phillips, et al.
Clinical Pharmacology in Drug Development
|
December 11, 2023
Population-Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease
Emmanuel O Fadiran, Edward Hammond, James Tran, et al.
Matrix Biology : Journal of the International Society for Matrix Biology
|
August 11, 2018
The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action
Marina Weissmann, Udayan Bhattacharya, Sari Feld, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|
February 20, 2014
Does access modality matter? Evaluation of validity in reusing clinical care data
Christopher P Danford, Monica M Horvath, W Edward Hammond, et al.
Page
of 7
Search research articles
Search
Showing results (11-20 of 62) with videos related to
Sort By:
Page
of 7
Frontiers in Oncology
|
August 9, 2014
The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics
Edward Hammond, Ashwani Khurana, Viji Shridhar, et al.
FEBS Open Bio
|
November 20, 2013
Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues
Edward Hammond, Paul Handley, Keith Dredge, et al.
Journal of AHIMA
|
August 12, 2009
Healthcare standards development. The value of nurturing collaboration
William Edward Hammond, Charles Jaffe, Rebecca Daniels Kush
Bioorganic & Medicinal Chemistry
|
October 31, 2007
Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88
Jon K Fairweather, Edward Hammond, Ken D Johnstone, et al.
Organic & Biomolecular Chemistry
|
August 19, 2007
Enantiospecific synthesis of the heparanase inhibitor (+)-trachyspic acid and stereoisomers from a common precursor
Steven C Zammit, Vito Ferro, Edward Hammond, et al.
British Journal of Clinical Pharmacology
|
July 10, 2023
The new big is small: Leveraging knowledge from small trials for rare disease drug development: Blarcamesine for Rett syndrome
Ene I Ette, Emmanuel O Fadiran, Christopher Missling, et al.
BMJ Open
|
November 19, 2015
Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study
Derek J Ward, Edward Hammond, Luan Linden-Phillips, et al.
Clinical Pharmacology in Drug Development
|
December 11, 2023
Population-Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease
Emmanuel O Fadiran, Edward Hammond, James Tran, et al.
Matrix Biology : Journal of the International Society for Matrix Biology
|
August 11, 2018
The heparanase inhibitor PG545 is a potent anti-lymphoma drug: Mode of action
Marina Weissmann, Udayan Bhattacharya, Sari Feld, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium
|
February 20, 2014
Does access modality matter? Evaluation of validity in reusing clinical care data
Christopher P Danford, Monica M Horvath, W Edward Hammond, et al.
Page
of 7